In the real world, the selection of a therapeutic modality like an antibody or peptide is often driven by a company's existing expertise and technology platform rather than a purely agnostic approach to finding the single best tool for a clinical problem. Organizations default to the tools in their toolbox.

Unlike large pharma where novel projects compete with established, safer alternatives, biotech startups derive immense power from their singular focus. The "live or die" mentality on a single hard problem forces teams to innovate and persevere through setbacks, which is essential for pushing true scientific boundaries.

Infinimmune’s platform bypasses traditional discovery methods by reading antibodies directly from human memory B cells. The core insight is that the immune system has already spent a lifetime selecting and validating the most effective antibodies, providing a superior, de-risked starting point for new human therapeutics.

Regeneron maintains a competitive edge by owning its antibody discovery platform (mice with humanized immune systems). This vertical integration provides full control and consistently yields best-in-class molecules, a feat competitors struggle to replicate even with access to similar third-party services.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

Biotech companies create more value by focusing on de-risking molecules for clinical success, not engineering them from scratch. Specialized platforms can create molecules faster and more reliably, allowing developers to focus their core competency on advancing de-risked assets through the pipeline.

The key attraction to InduPro wasn't just its novel science for predicting target pairs, but its integrated capability to build molecules based on those predictions. This fusion of a predictive engine and in-house biologics expertise creates a significant competitive moat.

Infinitopes' platform uses immunopeptidomics to directly measure peptides on a tumor's surface. This contrasts with competitors like Moderna and BioNTech, who rely on computational predictions from DNA sequencing. This "measure, don't predict" approach aims for more reliable identification of potent immune targets.

The venture creation strategy for platform biotechs isn't about finding one blockbuster drug. It's a binary bet: either the underlying scientific platform is sound and can repeatedly generate many medicines, or the entire concept fails. There is no middle ground of succeeding with just one product from the platform.